![Deanne King, M.D., Ph.D., (left) meets with TRI’s Kennetha Newman, the study’s lead research coordinator.](https://tri.uams.edu/wp-content/uploads/2023/02/Deanne-King-M.D.-Ph.D.-Kennetha-Newman-1024x576.jpg)
UAMS Principal Investigator: Deanne L. King, M.D., Ph.D., assistant professor and director of Clinical Research, College of Medicine Department of Otolaryngology – Head & Neck Surgery
Summary: A phase 3 multi-center trial will evaluate the safety and efficacy of a new drug candidate for Meniere’s disease.
Significance: There are few treatment options available for Meniere’s disease, a common inner ear disease whose symptoms include hearing loss, dizziness/vertigo and tinnitus. The anti-inflammatory drug candidate has shown promise as a treatment in smaller studies.
TRI Services: Medicare coverage analysis, study budget development, regulatory and nurse/clinical coordinator support, administration of Clinical Trial Management System, and post-award financial management.
Sponsor: Sound Pharmaceuticals Inc.